相关实验视频
Updated: Sep 15, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.2K
用托法西提尼布治疗的患者的多血管冠状动脉疾病:一个病例报告
Wongelawit Zerihun1, Joud Fahed1, Danhue Moodie1
1Department of Internal Medicine, Ascension Saint Agnes Hospital, Baltimore, USA.
Cureus
|July 18, 2025
概括
托法西提尼布是自身免疫性疾病的JAK抑制剂,可能会增加心血管事件的风险. 这一案例突显了这种药物治疗的风湿性关节炎患者的潜在心脏并发症.
科学领域:
- 免疫学 免疫学 免疫学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 托法西提尼布是一种口服的Janus激酶 (JAK) 抑制剂,用于治疗类风湿性关节炎等自身免疫性疾病.
- 雅克抑制剂调节炎症和免疫信号通路.
- 对托法西提尼布与心血管事件增加的关联存在担忧.
相关概念视频
Atherosclerosis III: Management
36
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
36
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
236
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
236
Coronary Artery Disease III: Clinical Manifestations
36
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
36
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Myocarditis III: Medical Management
16
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
16
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203

